Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

As part of its Single Technology Appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer (Merck Sharp & Dohme; MSD) of pembrolizumab (Keytruda(®)) to submit evidence of its clinical and cost effectiveness for the treatment of patients with r...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pharmacoeconomics
Main Authors: Grimm, Sabine E., Fayter, Debra, Ramaekers, Bram L. T., Petersohn, Svenja, Riemsma, Rob, Armstrong, Nigel, Pouwels, Xavier, Witlox, Willem, Noake, Caro, Worthy, Gillian, Kleijnen, Jos, Joore, Manuela A.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer International Publishing 2019
Assuntos:
Review Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6713293/
https://ncbi.nlm.nih.gov/pubmed/30895564
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-019-00792-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados